Influence of Interstitial Lung Disease on Outcome in Systemic Sclerosis: a Population-based Historical Cohort Study

Overview

Journal Chest

Publisher Elsevier

Specialty Pulmonary Medicine

Date 2013 Mar 2

PMID 23450327

Citations 14

Authors

Philippe R Bauer

Dante N Schiavo

Thomas G Osborn

David L Levin

Jennifer St Sauver

Andrew C Hanson

Darrell R Schroeder

Jay H Ryu

Affiliations

Soon will be listed here.

Abstract

Background: Interstitial lung disease (ILD) is a frequent complication of systemic sclerosis (SSc) and a major cause of SSc-related deaths. This study aimed to determine the influence of ILD on SSc in a population-based historical cohort study. The hypothesis was that patients with SSc who develop ILD have increased morbidity and mortality when compared with patients with SSc without ILD.

Methods: Using the record linkage system of the Rochester Epidemiology Project in Olmsted County, Minnesota, this study identified the incidence of SSc between 1980 and 2010 and point prevalence on December 31, 2010 and determined the progression of organ involvement and its influence on outcome.

Results: During the 30-year interval, we identified 64 incident cases of SSc: 57 women and seven men, median age 49.1 years (interquartile range [IQR], 39.8-67.6 years). There were 43 prevalent cases. ILD occurred in 19 cases, usually after the diagnosis of SSc (median, 2 years; IQR, 0-10 years), with only three cases occurring 6 to 24 months beforehand. Pulmonary arterial hypertension (PAH) was diagnosed in 14 cases, heart failure in 27 cases, and chronic kidney disease (CKD) in 21 cases. Seventeen patients died during the study period, with a median survival time after diagnosis of 22.9 years. ILD, PAH, and CKD were associated with an increased risk of death.

Conclusions: The incidence of ILD associated with SSc was relatively low in this population-based cohort. ILD appeared to be a contributing factor to mortality. Other factors, including age, PAH, and CKD, were also associated with poor outcome.

Citing Articles

Efficacy of Rituximab Versus Cyclophosphamide and Mycophenolate for the Treatment of Interstitial Lung Disease in Systemic Sclerosis: A Systematic Review.

Parikh A, Francis A, Sreenivasan C, Pandey M, AlQassab O, Kanthajan T Cureus. 2024; 16(8):e68279.

PMID: 39350831 PMC: 11441839. DOI: 10.7759/cureus.68279.

Heterogeneity of determining disease severity, clinical course and outcomes in systemic sclerosis-associated interstitial lung disease: a systematic literature review.

Petelytska L, Bonomi F, Cannistra C, Fiorentini E, Peretti S, Torracchi S RMD Open. 2023; 9(4).

PMID: 37940340 PMC: 10632935. DOI: 10.1136/rmdopen-2023-003426.

Epidemiology and Trends in Survival of Systemic Sclerosis in Olmsted County (1980-2018): A Population-based Study.

Coffey C, Radwan Y, Sandhu A, Crowson C, Bauer P, Matteson E J Scleroderma Relat Disord. 2022; 6(3):264-270.

PMID: 35295789 PMC: 8920411. DOI: 10.1177/23971983211026853.

Clinical phenotypes, hemodynamic characteristics and prognosis of Chinese patients with systemic sclerosis-associated precapillary pulmonary hypertension: a retrospective study.

Yuan Y, Yuan P, Su Y, Jiang R, Zhang R, He J Clin Rheumatol. 2022; 41(6):1675-1686.

PMID: 35099674 DOI: 10.1007/s10067-021-06016-8.

Journey of a patient with scleroderma from renal failure up to kidney transplantation.

Abbas F, Kossi M, Shaheen I, Sharma A, Halawa A World J Transplant. 2021; 11(9):372-387.

PMID: 34631469 PMC: 8465513. DOI: 10.5500/wjt.v11.i9.372.

References

Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

Mayes M, Lacey Jr J, Beebe-Dimmer J, Gillespie B, Cooper B, Laing T . Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003; 48(8):2246-55. DOI: 10.1002/art.11073. View

Steen V, Oddis C, Conte C, Janoski J, Casterline G, Medsger Jr T . Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963-1982. Arthritis Rheum. 1997; 40(3):441-5. DOI: 10.1002/art.1780400309. View

Lo Monaco A, Bruschi M, La Corte R, Volpinari S, Trotta F . Epidemiology of systemic sclerosis in a district of northern Italy. Clin Exp Rheumatol. 2011; 29(2 Suppl 65):S10-4. View

Guillevin L, Mouthon L . [Pulmonary involvement in systemic scleroderma]. Bull Acad Natl Med. 2011; 195(1):79-90. View

Melton 3rd L . History of the Rochester Epidemiology Project. Mayo Clin Proc. 1996; 71(3):266-74. DOI: 10.4065/71.3.266. View

Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G . Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore). 2002; 81(2):139-53. DOI: 10.1097/00005792-200203000-00004. View

Fischer A, Swigris J, Groshong S, Cool C, Sahin H, Lynch D . Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest. 2008; 134(3):601-605. DOI: 10.1378/chest.08-0053. View

Chang B, Wigley F, White B, Wise R . Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol. 2003; 30(11):2398-405. View

10.

Gabrielli A, Avvedimento E, Krieg T . Scleroderma. N Engl J Med. 2009; 360(19):1989-2003. DOI: 10.1056/NEJMra0806188. View

11.

. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980; 23(5):581-90. DOI: 10.1002/art.1780230510. View

12.

Renzoni E . Interstitial lung disease in systemic sclerosis. Monaldi Arch Chest Dis. 2008; 67(4):217-28. DOI: 10.4081/monaldi.2007.478. View

13.

Assassi S, Sharif R, Lasky R, McNearney T, Estrada-Y-Martin R, Draeger H . Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther. 2010; 12(5):R166. PMC: 2990992. DOI: 10.1186/ar3125. View

14.

Mayes M . Scleroderma epidemiology. Rheum Dis Clin North Am. 2003; 29(2):239-54. DOI: 10.1016/s0889-857x(03)00022-x. View

15.

Kurland L, Hauser W, FERGUSON R, HOLLEY K . Epidemiologic features of diffuse connective tissue disorders in Rochester, Minn., 1951 through 1967, with special reference to systemic lupus erythematosus. Mayo Clin Proc. 1969; 44(9):649-63. View

16.

LeRoy E, Black C, FLEISCHMAJER R, Jablonska S, Krieg T, Medsger Jr T . Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988; 15(2):202-5. View

17.

Tyndall A, Bannert B, Vonk M, Airo P, Cozzi F, Carreira P . Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010; 69(10):1809-15. DOI: 10.1136/ard.2009.114264. View

18.

Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J . Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum. 2007; 37(4):223-35. DOI: 10.1016/j.semarthrit.2007.05.003. View

19.

Highland K, Silver R . New developments in scleroderma interstitial lung disease. Curr Opin Rheumatol. 2005; 17(6):737-45. DOI: 10.1097/01.bor.0000181534.67685.5a. View

20.

Al-Dhaher F, Pope J, Ouimet J . Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum. 2008; 39(4):269-77. DOI: 10.1016/j.semarthrit.2008.06.002. View